You are here

Home » Content

Mide Kanserlerinde Preoperatif Serum CEA, CA19-9 ve AFP Düzeylerinin Klinikopatolojik Faktörlerle Korelasyonu

Corelation between Preoperative Serum CEA, CA19-9, and AFP Levels and Clinicopathologic Factors

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives: To investigate the correlation between preoperative serums CEA, CA19-9, and alphafetoprotein (AFP) levels and clinic pathological factors. Methods: The correlation between the records of pre-operative serum CEA, CA19-9, and alpha-fetoprotein levels and some clinic-pathological factors (tumor stage, liver metastasis, peritoneal metastasis, presence of ascites, unresectable tumors) of 74 patients with gastric adenocarcinoma operated in Ankara Yildirim Beyazit Education and Training Hospital 2nd Surgery Clinic was investigated. Results: Preoperative elevated serum CEA, CA19-9, and alpha-fetoprotein levels were found 31.4%, 30.3, and 16.4, respectively. While 31 (41.8%) out of 74 patients had one or more positive tumor markers, all three markers were found to be high in 8 patients (13.1%). Six of these patients were in stage 4, and the other two patients were in stage 3. Conclusion: Preoperative serum CEA, CA19-9, and alpha-fetoprotein levels were found high in patients with advanced stage, liver metastases, and unresectable gastric adenocarcinoma.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Gastrik adenokarsinomlu hastalarda preoperatif serum karsinoemriyonik antijen (CEA), CA19-9 ve alfa-fetoprotein (AFP) düzeyi ile klinikopatolojik faktörlerin korelasyonunu araştırmak. Metot: Gastrik adenokarsinom sebebiyle Ankara Yıldırım Beyazıt Eğitim Hastanesi 2. Cerrahi Kliniğinde ameliyat edilen 74 hastanın kayıtları retrospektif olarak incelendi. Hastaların preoperatif serum CEA, CA19-9, AFP düzeyleri ile bazı klinikopatolojik faktörler (tümör evresi, karaciğer metastazı, peritoneal metastaz, asit varlığı, tümörün rezeke edilebilirliği) arasındaki korelasyon araştırıldı. Bulgular: Hastaların preoperatif serum CEA, CA19-9, AFP pozitiflik oranları sırası ile %31.4, 30.3 ve 16.4 olarak bulundu. Hastaların 31’inde (%41,8) bir veya birden fazla tümör markırı yüksek iken, 8’inde (%13.1) üç markır da yüksek bulundu. Bu 8 hastanın 6’sı evre 4, 2’si evre 3 teki hastalardı. Sonuç: Gastrik adenokarsinomlu hastalarda preoperatif serum CEA, CA19-9, AFP seviyelerinin ileri evreli, karaciğer metastazı yapmış, rezektabıl olmayan tümörlerde anlamlı oranda yüksek olduğu görüldü.
FULL TEXT (PDF): 
PDF icon arastirmax-mide-kanserlerinde-preoperatif-serum-cea-ca19-9-afp-duzeylerinin-klinikopatolojik-faktorlerle-korelasyonu.pdf
  • 4
233-237
  • Turkish

REFERENCES

References: 

1. Komada I, Koufuji K, Kawabata S, et al. The clinical efficacy of CA72-4 as
serum marker for gastric cancer in comparison with CA19-9 and CEA. İnt
Surg 1995;80:45-8.
2. Hyodo T, Kawamoto R – Double cancer of the stomach, one AFP –
producing tumor. J Gastroenterol 1996;31:851-854
3. Koide N, Nıshıo A, Igarashı J, Kajıkawa S, Adachi W, Amano J. Alpha
fetoprotein –producing gastric cance: histochemical analysis of cell
proliferaten, apoptosis, and angiogenesis. Am J gastroenterol 1999; 94:1658-
1663.
4. Torre GC, Lucchesse V, Rembado R, Barbetti V ; Tumor markrs ; from
labratory to clinical use . Anticancer Res 1996; 16:2215-2220.
5. Holyeke ED, Chu TM, Murphey GP. CEA as a monitor of gastrointestinal
malignancy. Cancer 1975; 35:830-836.
6. Staab HJ, Anderer FA, Brummendorf T, et al. Prognostik value of
preoperative CEA comperad to clinical stageing : 2 Gastric cancer . Br J
Cancer 1982;45:718-727.
7. Kohler JP, Simoniwitz D, Paloyan D, Preoperative CEA leve : A prognostik
test in patien ts with colorectal carcinoma . Am Surg 1980; 46:449-452.
8. Tamada R, Hiramoto Y, Abey S, Nozuka T, Okumura T, Masuda H, Kano
T, Kumashiro R, Inokuchi K. Serial determinations of CEA for detections of
recurrant gastric cancer . Jpn J Surg 1982;12:429-433.
9. Marelli D , Roviello F, De Stefano A. Serum levels in gastric carcinoma.
Oncology 1999;57: 55-62.
10. Kodera Y, Yamamura Y, Torii A, Yasui K, Morimoto T, Kato T, Kito T.
The prognostic value of preoperatif Serum levels of CEA and CA19-9
inpatient with gastric cancer: The American Journal of gastroenterology
1996; 91:149-53.
11. Nakane Y, Okamura S, Akehira K, Koiki K. Corelation of preoperative
CEA levels and prognosis of gastric cancer patients. Cancer 1994;73: 2703 -
2708.
12. Koga K, Kano T, Sounda K, Kioki K. The clinical usefulness of preoperative
CEA determination in gastric cancer. Japanase Journal of Surgery 1987;17:
342-347.
13. Shimizu N, Wakutsuki T, Murakami A, Maeta M, Koga S. CEA in gastric
patients. Oncology 1987;44: 240-244.
14. Dittrich C, Jakaesz R, Havelec L, et al. CEA plasma level determination in
the managemeof gastric cancer patients. Cancer Determinattion and
Prevention 1985;8: 181-187.
15. Yoshihiko M, Keizo S, Masanobu A. Serum CEA level increseases correlate
with tumor progression in patients with differentiated gastric carcinoma
following noncurative resection . Cancer Research 50(11) (1990) pp.3952-55.
16. Kornek G, Depisch D, Temsch EM, Scheithauer W. Comperative analaysis
of cancer associated antigen CA195, CA 19-9 and CEA in diagnosis , fallowup
and monitoring to response to chemotherapy in patient s with
gastrointestinal cancer . J. Cancer Res Clin Oncol 1991;117:493-496.
17. Baillari P, Sammaritino P, Cardi M, Cerasi A. Gastrointestinal cancer fallow
up : The effectiveness of secuantial CEA ; TPA and CA19-9 evaluation in the
early diagnosis of recurances. Aust N Z J Surg 1991;61:675-680.
18. Takahashi Y, Takeuchı T, Sakamoto J, et al.The usefulness of CEA and/ or
CA19-9 in monitoringfor reccurance in gastric cancer patients: a prospective
clinical study. Gastric Cancer 2003; 6: 142-145.
19. Nakajima K, Ochiai T, Suziki T, Shimada H, Hayashi H, Yasumatu A.
Impct of preoperative serum CEA, CA19-9,AFP levels in gastric cancer
patients . Tumor Biol.1998; 19: 464-469.
20. Lee R , Rha SY, Ahn JB, Shim KY, Choi JH, Lim HY, Yoo NC, Noh SH,
Kim JH, Kim SB, Chung HC. Alpha –Fetoprotein producing gastric cancer.
Oncol Rep. 1998;5:1179-84.
21. Altınbaş E, Polat H, Borazan A, Yeksan M, Ecirli Ş. Mide kanserli olgularda
tümör markırlarından AFP, CEA, CA 125 ve CA 19-9’un klinik
kullanımlarının incelenmesi. Selçuk Üniv. Tıp Fak. Dergisi 2001;17(1):37-42
22. Kayaalp C, Arda K, Orug T, Ozcay N. Value of computed tomography in
addition to ultrasound for preoperative staging of gastric cancer. European
Journal of Sugical Oncology. 2002; 26: 1-4.
23. De Graaf GW, Avantude AA, Parsons SL, Duffy JP, et al. The role of staging
laparoscopy in oesophagogastric cancers. Eur. J. Surg. Oncol. 2007; 33: 988-
92.

Thank you for copying data from http://www.arastirmax.com